Patient info Open main menu

Mitotane Esteve® 500 mg tablets – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
500 mg
Contains active substance:
ATC code:

Patient leaflet - Mitotane Esteve 500 mg tablets

1. What Mitotane Esteve is and what it is used for

Mitotane Esteve is an antitumoral medicine.

This medicine is used for the treatment of symptoms of advanced non operable, metastatic or recurrent malignant tumours of the adrenal glands.

2. What you need to know before you take Mitotane Esteve

Do not take Mitotane Esteve

  • if you are allergic to mitotane or any of the other ingredients of this medicine (listed in section 6).
  • if you are breast-feeding. You must not breast-feed while taking Mitotane Esteve.
  • if you are being treated with medicines containing spironolactone (see "Other medicines and Mitotane Esteve").

Warnings and precautions

Talk to your doctor or pharmacist before taking Mitotane Esteve. You should tell your doctor if any of the following applies to you:

  • if you have an injury (shock, severe trauma), an infection or if you have any illness while you are taking Mitotane Esteve. Tell your doctor immediately, who may decide to temporarily stop treatment.
  • if you have liver problems: Tell your doctor if you develop any of the following signs and symptoms of liver problems during Mitotane Esteve treatment: itching, yellow eyes or skin, dark urine, and pain or discomfort in the right upper stomach area. Your doctor should do blood tests to check your liver function before and during treatment with Mitotane Esteve, and as clinically indicated. Your doctor may decide to interrupt Mitotane Esteve treatment.

    • if you have severe kidney problems.
    • if you are using any medicines mentioned below (see "Other medicines and Mitotane Esteve").
    • if you have gynaecological problems such as vaginal bleeding, menstrual disorders and/ or pelvic pain.

This medicine should not be handled by persons other than the patient and his/her caregivers, and especially not by pregnant women. Caregivers should wear disposable gloves when handling the tablets.

During treatment with Mitotane Esteve

Mitotane Esteve may temporarily lower the amount of hormones produced by your adrenal gland (cortisol) but your doctor will correct this using appropriate hormone medication (steroids).

Mitotane Esteve can cause bleeding that lasts longer than usual. If you need to have surgery or dental procedures during treatment with Mitotane Esteve, your healthcare provider will do blood tests to check for prolonged bleeding risks.

Other medicines and Mitotane Esteve

Please tell your doctor or pharmacist if you are using or have recently used any other medicines, including medicines obtained without a prescription.

You must not use Mitotane Esteve with medicines containing spironolactone, often used as a diuretic for heart, liver or kidney diseases.

Mitotane Esteve may interfere with several medicines. Therefore, you should tell your doctor if you are using medicines containing any of the following active substances:

  • warfarin or other anticoagulants (blood thinners), used to prevent blood clots. The dose of your anticoagulant may need adjustment.
  • antiepileptics
  • rifabutin or rifampicin, used to treat tuberculosis
  • griseofulvin, used in the treatment of fungal infections
  • herbal preparations containing St. John’s wort (Hypericum perforatum)
  • sunitinib, etoposide: to treat cancer
  • midazolam, used as sedative

Mitotane Esteve with food and drink

Mitotane Esteve should preferably be taken during meals containing fat-rich food such as milk, chocolate, oil.

Pregnancy, breast-feeding and fertility

Mitotane Esteve may harm the foetus. If you are pregnant, think you are pregnant or are planning to become pregnant, tell your doctor as soon as possible to know if you should stop or continue Mitotane Esteve.

If you may become pregnant, you should use an effective contraception during treatment with Mitotane Esteve and even after stopping it, ask your doctor for advice.

Because of the potential for serious adverse reactions in your baby, you must not breast-feed while taking Mitotane Esteve and even after stopping it. Ask your doctor for advice.

Driving and using machines

Mitotane Esteve has a major influence on your ability to drive and use machines. Ask your doctor for advice.

3. How to take Mitotane Esteve

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

Dose and schedule

The usual starting dose for adults is 2 to 3 g (4 to 6 tablets) per day. Your doctor may start treatment at higher doses such as 4 to 6 g (8 to 12 tablets).

In order to find the optimal dose for you, your doctor will monitor regularly the levels of Mitotane Esteve in your blood. Your doctor may decide to stop treatment with Mitotane Esteve temporarily or to lower the dose if you experience certain side effects.

Use in children and adolescents

The starting daily dose of Mitotane Esteve is 1.5 to 3.5 g/m2 body surface area (this will be calculated by your doctor according to the weight and the size of the child). The experience in patients in this age group is very limited.

Method of administration

You should swallow the tablets with a glass of water during meals containing fat-rich food. You can divide the total daily dose in two or three intakes.

If you take more Mitotane Esteve than you should

Tell your doctor immediately if you have taken accidentally more Mitotane Esteve than you should or if a child has accidentally swallowed some.

If you forget to take Mitotane Esteve

If you accidentally miss a dose, just take the next dose as scheduled. Do not take a double dose to make up for the forgotten one.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, Mitotane Esteve can cause side effects, although not everybody gets them.

Tell your doctor immediately if you experience any of the following side effects:

  • Adrenal insufficiency: fatigue, abdominal pain, nausea, vomiting, diarrhoea, confusion
  • Anaemia: cutaneous pallor, muscular fatigability, feeling breathless, vertigo especially when standing up

    • Liver damage: yellowing of the skin and eyes, itching, nausea, diarrhoea, fatigue, dark coloured urine
    • Neurological disorders: movement and coordination disorders, abnormal sensations like pins and needles, memory loss, concentration difficulty, difficulty to talk, vertigo

These symptoms may reveal complications for which specific medication could be appropriate.

Side effects may occur with certain frequencies, which are defined as follows:

  • very common: may affect more than 1 in 10 people
  • common: may affect up to 1 in 10 people
  • not known: frequency cannot be estimated from the available data

Very common side effects

  • vomiting, nausea (feeling sick), diarrhoea, belly pain
  • lack of appetite
  • abnormal sensations like pins and needles
  • movement and coordination disorders, vertigo, confusional state
  • feeling sleepy, fatigue, muscle weakness (fatigue of muscle during effort)
  • inflammation (swelling, heat, pain) of mucosa, skin rash
  • blood disorders (bleeding time prolonged)
  • increase of cholesterol, triglycerides (fats) and liver enzymes (in blood tests)
  • decrease in white blood cells count
  • breast overdevelopment in men
  • adrenal insufficiency (may cause fatigue, abdominal pain, nausea, vomiting, diarrhoea, confusion)

Common side effects

  • dizziness, headache
  • peripheral nervous system disorders (association of sensory disorders, muscular weakness and atrophy, decrease of tendon reflex and vasomotor symptoms such as hot flushes, sweat and sleep disorders)
  • mental impairment (such as memory loss, concentration difficulty)
  • movement disorder
  • decrease of red blood cells (anaemia, with symptoms such as skin pallor and fatigue), decrease in blood platelets (may make you more prone to bruising and bleeding)
  • hepatitis (auto-immune) (may cause yellowing of the skin and eyes, dark coloured urine)
  • difficulty of coordinating muscles

Frequency Not Known

  • fever
  • general aching
  • flushing, high or low blood pressure, feeling of dizziness/vertigo when you suddenly stand up
  • increased production of saliva
  • eye disorders: visual impairment, vision blurred, double vision, distortion of images, complain of glare

    • opportunistic infection
    • liver injury (may cause yellowing of the skin and eyes, dark coloured urine)
    • decreased uric acid in blood tests
    • bladder inflammation with bleeding
    • presence of blood in urine, presence of proteins in urine
    • balance disorder
    • distortion of the sense of taste
    • impaired digestion
    • ovarian macrocysts (with or without symptoms such as pelvic pain, vaginal bleeding, menstrual disorders)
    • decreased androstenedione (precursor of sex hormones) in blood tests in females
    • decreased testosterone (sex hormone) in blood tests in females
    • sex hormone binding globulin (a protein which binds sex hormones) increased in blood tests
    • corticosteroid binding globulin increased in blood tests
    • thyroxin binding globulin increased in blood tests
    • decreased free testosterone (sex hormone) in blood tests in males
    • hypogonadism in males (with symptoms such as breast overdevelopment, libido decreased, erectile dysfunction, fertility disorders)
    • allergic reactions, itching

In children and adolescents, thyroid problems, neuro-psychological, growth retardation and one case of encephalopathy have been observed. In addition, some signs of hormonal changes (such as breast overdevelopment in males and vaginal bleeding and/or early breast development in females) have been observed.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme

Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Mitotane Esteve

Keep this medicine out of the sight and reach of children.

Store in the original packaging. After opening: 1 year.

Do not use this medicine after the expiry date which is stated on the carton and the bottle after EXP.

Any unused product or waste material should be disposed of in accordance with local requirements for cytotoxic medicines.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Mitotane Esteve contains

  • The active substance is mitotane. Each tablet contains 500 mg of mitotane.
  • The other ingredients are maize starch, microcrystalline cellulose (E 460), macrogol 3350 and silica colloidal anhydrous.

What Mitotane Esteve looks like and contents of the pack

Mitotane Esteve tablets are white, biconvex, round and scored. Mitotane Esteve is available in plastic bottles of 100 tablets.

Marketing Authorisation Holder

Esteve Pharmaceuticals S.A.

Passeig de la Zona Franca 109 Planta 4

08038 Barcelona

Spain

+34 93 446 60 00

Manufacturer

CENTRE SPECIALITES PHARMACEUTIQUES

76-78, avenue du Midi

63800 COURNON D’AUVERGNE

FRANCE

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

This leaflet was last revised in 03/2026

Other sources of information

Detailed information on this medicine is available on the MHRA web site: https://products.mhra.gov.uk/. There are also links to other websites about rare diseases and treatments.

This leaflet is available in all European languages on the EMA website.

Folder n° : 260641
PRODUCT NAMEMITOTANE ESTEVE
119101502
119101501
TYPELeaflet
STRENGTH(S)500 mg
PHARMA. FORMTablet
ZONE-
COUNTRYUK
LANGUAGEEN
MANUFACTURERCSP
FORMAT650 x 210 mm
TECH. LAYOUT REF.-
PRINTED COLOURS
-
FONTDax Pro - Roundest Serial
9 pts
SOFTWAREIndesign CC
BAR CODES-
DATE (day/month/year)20/03/2026
2

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 08498/0040

Last revision stated in the text: March 2026 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Mitotane Esteve 500 mg tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Mitotane
Strength 500 mg
Pharmaceutical form Oral tablet
How is it taken Oral
Pack sizes 100 tablet
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Drug group (ATC)
  1. L Antineoplastic and immunomodulating agents
    1. L01 Antineoplastic agents
      1. L01X Other antineoplastic agents
        1. L01XX Other antineoplastic agents
          1. L01XX23 mitotane
Marketing authorisation PL 08498/0040
Codes GTIN 8431506001826 · BNF 08010500

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.